Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-23-000017
Filing Date
2023-05-01
Accepted
2023-05-01 09:25:13
Documents
61
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sava-20230331x10q.htm   iXBRL 10-Q 1745665
2 EX-31.1 sava-20230331xex31_1.htm EX-31.1 25544
3 EX-31.2 sava-20230331xex31_2.htm EX-31.2 25243
4 EX-32.1 sava-20230331xex32_1.htm EX-32.1 20220
5 GRAPHIC sava-20230331x10qg001.jpg GRAPHIC 62088
6 GRAPHIC sava-20230331x10qg002.jpg GRAPHIC 77567
7 GRAPHIC sava-20230331x10qg003.jpg GRAPHIC 93477
  Complete submission text file 0001069530-23-000017.txt   6297367

Data Files

Seq Description Document Type Size
8 EX-101.SCH sava-20230331.xsd EX-101.SCH 31192
9 EX-101.CAL sava-20230331_cal.xml EX-101.CAL 34839
10 EX-101.DEF sava-20230331_def.xml EX-101.DEF 104132
11 EX-101.LAB sava-20230331_lab.xml EX-101.LAB 250111
12 EX-101.PRE sava-20230331_pre.xml EX-101.PRE 222761
55 EXTRACTED XBRL INSTANCE DOCUMENT sava-20230331x10q_htm.xml XML 992874
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 23870623
SIC: 2834 Pharmaceutical Preparations